PWMG
CTKB icon

Prestige Wealth Management Group’s Cytek Biosciences CTKB Stock Holding History

Prestige Wealth Management Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05K Hold
240
– – ﹤0.01% 853
2025
Q4 		$1.21K Hold
240
– – ﹤0.01% 845
2025
Q3 		$833 Buy
+240
New +$901 ﹤0.01% 879

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prestige Wealth Management Group's CTKB Position: Q1 2026 in Review

Prestige Wealth Management Group held its Cytek Biosciences (CTKB) position steady in Q1 2026 at 240 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Prestige Wealth Management Group first reported a position in CTKB in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.21K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Prestige Wealth Management Group held 240 shares of Cytek Biosciences worth $1.05K as of Q1 2026.
  • Prestige Wealth Management Group left its Cytek Biosciences share count unchanged in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q1 2026, its #853 holding.
  • Prestige Wealth Management Group first reported a position in Cytek Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Prestige Wealth Management Group's Cytek Biosciences position peaked at $1.21K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Prestige Wealth Management Group's 13F filing for Q1 2026, filed 13 May 2026.